FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 08:35:37 2024-05-22 am EDT | ||
| 185.8 EUR | +10.26% |
|
| Current month | +22.51% | ||
| 1 month | +118.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 185.8 | +10.26% |
| 24-05-21 | 168.5 | +15.32% |
| 24-05-20 | 146.1 | -0.90% |
| 24-05-17 | 147.5 | +17.97% |
| 24-05-16 | 125 | +4.11% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 08:35 am EDT
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ43TW |
| ISIN | DE000SQ43TW7 |
| Date issued | 2022-12-06 |
| Strike | 81.05 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.09 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 186.8 € |
|---|---|
| Lowest since issue | 9.52 € |
| Spread | 7.52 € |
| Spread % | 3.93% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.27
USD
Average target price
53.19
USD
Spread / Average Target
+25.84%
- Stock Market
- Certificates
- Certificat
